Gilead Sciences, Inc. (BVMF:GILD34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 813.92B +12.4% |
| Revenue (ttm) | 155.12B +3.5% |
| Net Income | 48.08B +54.5% |
| EPS | 38.36 +55.4% |
| Shares Out | n/a |
| PE Ratio | 16.93 |
| Forward PE | n/a |
| Dividend | 5.78 (1.78%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 20 |
| Average Volume | 106 |
| Open | 323.84 |
| Previous Close | 328.68 |
| Day's Range | 323.84 - 323.84 |
| 52-Week Range | 293.72 - 396.35 |
| Beta | 0.33 |
| RSI | 37.71 |
| Earnings Date | May 7, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
RBC Capital remains ‘conservative’ on Gilead’s Trodelvy and Yeztugo
RBC Capital keeps a Sector Perform rating and $122 price target on Gilead (GILD) after hosting the RBC healthcare conference with a presentation by the company CMO. There was high…
Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target The company’s growth in the base business is expected to reach 5%-6%, exceeding the…
Gilead upgraded to Buy from Hold at Maxim
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target
Gilead Sciences Transcript: RBC Capital Markets Global Healthcare Conference 2026
Key updates include positive Trodelvy data in breast and lung cancer, acquisition of Tubulis for novel ADCs, and expansion of anito-cel CAR T into earlier myeloma lines. The inflammation portfolio is advancing, and HIV prevention/treatment options are expanding with once-yearly and weekly regimens.
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
Gilead Sciences NASDAQ: GILD Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammat...
Gilead Prices $3 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, tod...
Gilead to present new data on PBC, viral hepatitis at EASL 2026
Gilead (GILD) Sciences will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver Congress, May 27-30, 2026, Barcelona. These...
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of t...
Gilead Sciences Transcript: Bank of America Global Healthcare Conference 2026
The session highlighted strong growth in HIV and oncology, with updated guidance and major acquisitions in cell therapy, ADCs, and inflammation. Long-acting HIV prevention and treatment products are driving market expansion, while oncology assets like Trodelvy and anito-cel are positioned for significant growth.
Gilead price target lowered to $168 from $175 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Gilead (GILD) to $168 from $175 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Gilead price target raised to $157 from $155 at Truist
Truist raised the firm’s price target on Gilead (GILD) to $157 from $155 and keeps a Buy rating on the shares. The company delivered Q1 top- and bottom-line beats with…
Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Gilead Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 8% year-over-year base business growth, led by HIV, oncology, and liver disease. YEZTUGO and TRODELVY outperformed, prompting a $400M increase in 2026 revenue guidance. Multiple acquisitions and regulatory milestones are set to further strengthen the pipeline.
Gilead Sciences Slides: Q1 2026
Gilead Sciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Gilead Sciences Earnings release: Q1 2026
Gilead Sciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Gilead Sciences Quarterly report: Q1 2026
Gilead Sciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for the year due to charges and financing costs r...
Gilead Sciences Announces First Quarter Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2026. “Gilead teams have delivered another strong...
Options Volatility and Implied Earnings Moves Today, May 07, 2026
Today, several major companies are expected to report earnings: Gilead Sciences (GILD), McDonald’s (MCD), Trade Desk (TTD), DraftKings (DKNG), Airbnb (ABNB), Rocket Lab USA (RKLB), Coinbase Global (CO...
Gilead Sciences Slides: Investor presentation
Gilead Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--Gilead's Earnings per Share Expected to Be Up 52% as Florida's and other States' AIDS Drug Programs Falters, says AHF.
Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients are interested in the new option a...
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.